Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab in advanced ovarian cancer
NCT00058552Phase 2Completed
- Sponsor
- Genentech
- Start
- May 2003
- Primary completion
- Jul 2004
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of pertuzumab in ovarian cancer, sponsored by Genentech. Primary endpoint: Objective Response Rate. Started May 2003; status: completed.
02
Drugs
pertuzumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00058552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058552.